YGEN.L Regulatory News (YGEN)

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Directorate Change

Manchester, UK - 25 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director ("NED") and Chair of the Audit Committee at Yourgene with effect from today.

Mary has extensive experience in the healthcare sector, having previously been Chief Financial Officer and board member of AIM listed Advanced Medical Solutions plc ("AMS") for 19 years during which the company saw 15 years of consecutive growth. Mary is a Member of the Chartered Institute of Management Accountants (ACMA) and a Fellow of the Association of Corporate Treasurers (FCT). Mary has a degree in Chemistry from the University of Oxford.

Mary is also a Senior Independent NED of Abingdon Health and NED for Allergy Therapeutics plc.

Separately the Group announces that Nick Mustoe has left the Board with immediate effect. We wish to thank Nick for all his support during his time at Yourgene and wish him the best for the future.

Adam Reynolds, Non-Executive Chairman, commented: "Mary has extensive experience within the life sciences sector on AIM, which will be invaluable to the Group as we grow and expand. I look forward to working alongside Mary as we continue to engage with our extensive pipeline of exciting opportunities.

"I would also like to thank Nick for his time and support of the Group. Nick has worked with Yourgene since the Company's IPO in 2014 and we have greatly benefitted from his expertise and guidance. Nick remains a supportive shareholder in Yourgene and I wish him all the best in his future endeavours."

Disclosures in accordance with the AIM Rules

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Mary Geraldine Tavener (aged 60):

Mary Tavener does not hold any share or options in the Company.

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.